



**Minutes of the Extraordinary General Meeting of Shareholders No. 49  
for the Year 2026 of Aikchol Hospital Public Company Limited**

**Date and Venue**

The Extraordinary General Meeting of Shareholders No. 49 for the Year 2026 was held on May 7, 2026, at 10:00 a.m. via electronic media (e-EGM). The meeting was conducted in accordance with the Royal Decree on Electronic Meetings, B.E. 2563 (2020) and other relevant regulations. The live broadcast of the meeting was stationed at Meeting Room 1, 3rd Floor, Aikchol Hospital Angsila, located at No. 31/2, Moo 3, Angsila Road, Samet Sub-district, Mueang District, Chonburi Province.

**The Company's directors participating via electronic media**

- |    |                       |                    |   |
|----|-----------------------|--------------------|---|
| 1) | Mr. Apirag            | Vanich             | Chairman  |
| 2) | Ms. Kanchana          | Vanich             | Director  |
| 3) | Ms. Oranuj            | Vanich             | Director  |
| 4) | Mrs. Thitawat         | Pothanant          | Independent Director /<br>Member of Audit Committee /<br>Member of the Nomination and<br>Remuneration Committee |
| 5) | Assoc.Prof.Dr.Sarayut | Rueangsuwan, Ph.D. | Director / Member of the Nomination and<br>Remuneration Committee   |
| 6) | Assoc.Prof.Pongsak    | Yuktanandana, M.D. | Independent / Member of Audit Committee   |
| 7) | Mr. Kiattiporn        | Sirichaisakul      | Independent / Member of Audit Committee   |
| 8) | Mr. Bordin            | Sabsomboon         | Director  |

**Representing 100 percent of the total number of the Company's directors.**

**Company executives attending the meeting at Meeting Room 1, 3rd Floor, Aikchol Hospital Angsila**

- |    |                   |                         |   |
|----|-------------------|-------------------------|---|
| 1) | Mr. Siriphot      | Manoch                  | Assistant Chairman of the Executive Officer,<br>Corporate Strategy Division |
| 2) | Mr. Nopparuj      | Potcharakotchanun, M.D. | Hospital Director (Aikchol Hospital)  |
| 3) | Mr. Kesada        | Chandsawang, M.D.       | Hospital Director (Aikchol Hospital Angsila)                                |
| 4) | Mrs. Pariyanath   | Chalermchuang           | Chief Accounting and Finance Officer  |
| 5) | Ms. Daraphan      | Sakornsathien           | Chief Marketing Officer   |
| 6) | Ms. Chalapim      | Chaisuttinan            | Director of Nursing Department  |
| 7) | Mr. Sidthiphot    | Manoch                  | Deputy Director of Accounting and Finance                                   |
| 8) | Ms. Thanatchaporn | Sukha                   | Financial & Accounting Manager  |
| 9) | Mrs. Wilailux     | Srisuwan                | Company Secretary   |



**Other attendees participating via electronic media**

- |    |                |              |  |
|----|----------------|--------------|--|
| 1) | Mr. Pipat      | Pipatphajong | Legal Advisor from ILCT Co.,Ltd.                           |
| 2) | Ms. Praneetsin | Foythong     | Representative of Auditor from Dharmniti Auditing Co.,Ltd. |
| 3) | Ms. Potjanarat | Siripipat    | Representative of Auditor from Dharmniti Auditing Co.,Ltd. |

**Other observers from the Corporate Governance Department, the Stock Exchange of Thailand, participating via electronic media**

- |    |                  |           |  |
|----|------------------|-----------|--|
| 1) | Ms. Narisara     | Pongklam  | Officers from the Stock Exchange of Thailand |
| 2) | Ms. Phatharaporn | Monghasab | Officers from the Stock Exchange of Thailand |

**Meeting Commencement**

Mrs.Wilailux Srisuwan, the Company Secretary, informed the meeting of the shareholder registration details at the commencement of the meeting at 10:00 a.m., as follows:There were 8 shareholders attending the meeting in person, holding a total of 33,548,980 shares, and 28 proxies recorded in the system, holding a total of 57,940,786 shares.This amounted to a total of 36 participants, representing a total of 91,489,766 shares or 61.0301 percent of the Company's total issued and paid-up shares (which stand at 149,909,264 shares). This constituted a quorum in accordance with the law and the Company's Articles of Association.

Mr.Apirak Vanich ("the Chairman") then called the Extraordinary General Meeting of Shareholders No. 49 for the Year 2026 to order, and summarized the voting and counting procedures for the meeting as follows

Each shareholder or proxy shall have a number of votes equal to the number of shares held. For shareholders who have appointed a proxy using Proxy Form B to allow another person or an independent director to attend and vote on their behalf, and have specified their voting intentions, the Company will record and cast the votes in accordance with the shareholders' wishes.

Foreign shareholders who have appointed a custodian in Thailand as their share depository and supervisor may split their votes into "Approve," "Disapprove," or "Abstain" for each agenda item. The split votes must equal the total number of shares held.

Upon completion of the consideration for each agenda item, the Company Secretary will request shareholders and proxies to cast their votes. Those who wish to vote "Disapprove" or "Abstain" are requested to click on the voting link, in accordance with the guidelines that will be provided to the shareholders accordingly.



The Company Secretary informed the meeting that for the Minutes of the 48th Annual General Meeting of Shareholders, held on April 23, 2026, the Company will submit the minutes to the relevant authorities and publish them on the Company's website from 5:00 p.m. on May 7, 2026, onwards. Shareholders may review the said minutes and, should there be any amendments, may notify the Company Secretary during regular business hours within a one-month period, from May 8, 2026, to June 8, 2026.

The Company Secretary then requested the meeting's permission to amend the voting requirements specified on page 1 of the notice of the meeting under Agenda Item [\*] regarding the resolution. This was because, for this particular agenda, the resolution must be passed by not less than three-fourths (3/4) of the total votes of the shareholders present and eligible to vote.

Additionally, the Company Secretary informed the meeting that this Extraordinary General Meeting of Shareholders would be video-recorded throughout the entire session, and the recording would be published on the Company's Investor Relations website. Having completed the briefing on all meeting details, the Company Secretary invited the Chairman to officially commence the meeting in accordance with the agenda items specified in the notice of the meeting as follows:

**Agenda 1 To consider and approve the removal of directors before the expiration of their term of office**

The Chairman informed the meeting that, in order to ensure the orderly management and maintain the best interests of the Company, the Board of Directors' Meeting No. 368, held on March 23, 2026, resolved to remove Dr. Jakkaphan Pongsethian from his position as Chief Executive Officer (CEO), effective from March 23, 2026.

Since Dr. Jakkaphan Pongsethian also holds positions as a director and an authorized director of the Company, the consideration for the removal of an authorized director must comply with Article 23 (4) of the Company's Articles of Association. Accordingly, the shareholders' meeting must pass a resolution by not less than three-fourths (3/4) of the total number of shareholders present and eligible to vote, holding not less than half (1/2) of the total shares held by the shareholders present and eligible to vote, to approve the removal of the said director from his positions as director and authorized signatory of the Company.

The Chairman then invited the Company Secretary to explain the details related to this agenda item to the meeting on behalf of the Chairman.

The Company Secretary informed the meeting that, to ensure conformity with the Principles of Good Corporate Governance, the Company would like to clarify the procedures for inquiries, voting, and vote counting relevant to this agenda item as follows:



1. Shareholders who have questions may click the "Raise Hand" button. The staff will then enable your microphone, after which you must unmute the microphone on your own device to ask your question. Alternatively, if you prefer, you may type and submit your questions through the Q&A channel.

2. To cast a vote, participants who wish to vote must switch from the "E-Meeting" window in their browser and click the "E-Voting" button. A new window will appear for voting, where you can select either "Approve," "Disapprove," or "Abstain." After making your selection, a pop-up window will appear asking to confirm your vote; please click "OK" to finish.

3. Once you have successfully confirmed your vote, the selected voting option will turn green. \*Please note that after the voting period has ended and the agenda item has been closed, attending shareholders will no longer be able to cast or change their votes.

4. After you have completed your voting, please return to the E-Meeting (Zoom) window to continue viewing the meeting's video and audio broadcast. The staff will compile all votes from the voting system and present the final results to everyone once the vote counting is complete.

The questions, answers, and opinions regarding this agenda item are summarized and presented in the appendix attached to these minutes.

When there were no further inquiries from the shareholders, the Company Secretary opened the voting session and informed the meeting that this agenda item required an affirmative resolution of not less than three-fourths (3/4) of the total votes of the shareholders present and eligible to vote, and holding not less than half (1/2) of the total shares held by the shareholders present and eligible to vote.

**Meeting's Resolution:** The meeting considered the matter and resolved, by a vote of not less than three-fourths (3/4) of the total votes of the shareholders present and eligible to vote, and holding not less than half (1/2) of the total shares held by the shareholders present and eligible to vote, to approve the removal of Dr. Jakkaphan Pongsethian from his positions as director and authorized signatory of the Company before the expiration of his term of office, with the following voting results:



Vote	Number of Votes	% of Total Votes*	Number of Shareholders Present and eligible to vote (Person/s)	Percentage (%)
Approve	91,511,749	100.0000	34	94.0000
Disapprove	0	0.0000	0	0.0000
Abstain	13	-	2	6.0000
Void	0	0.0000	0	0.0000
<b>Total</b>	<b>91,511,762</b>	<b>100.0000</b>	<b>36</b>	<b>100.0000</b>

\*Percentage of the total votes of shareholders and proxies present and eligible to vote.

#### **Agenda 2 Other matters (if any)**

-None-

The Chairman informed the meeting that since there were no other matters to be considered, the Chairman opened the floor for shareholders to ask questions or express their opinions. As there were no further comments or questions from the shareholders, the Chairman expressed his gratitude to all shareholders for attending the meeting and for their continued support of the Company, and officially adjourned the meeting.

The meeting closed at 10:30 AM.

Sign.....Mr. Apirag Vanich.....The Chairperson of the Meeting  
(Mr. Apirag Vanich)

Sign.....Mrs. Wilailux Srisuwan.....Company Secretary  
(Mrs. Wilailux Srisuwan)

Meeting Minutes



## Attachments

### Questions - Answers

#### Minutes of the Extraordinary General Meeting of Shareholders (49<sup>th</sup>)

#### Aikchol Hospital Public Company Limited

---

**Mr. Wanchai Lertsrijatuporn, a Shareholders' Rights Protection Volunteer, acting as a proxy for the Thai Investors Association.**

**Question 1:** "The Company stated that this removal is for 'orderly management and the best interests of the Company.' I would like the Board of Directors to elaborate on which specific areas of duty, plan, or KPI Dr. Jakkaphan failed to meet that significantly impacted the orderly operations of the business."

**Answer 1:** Regarding the point raised that this removal is for the "orderly management and the best interests of the Company," the Board of Directors utilized such phrasing based on systematic evaluation results and factual evidence. It appears that in 2025, the key financial indicators approved by the Board were significantly lower than budgeted, namely: revenue was 14.7 percent below budget, EBITDA was 24.7 percent below budget, adjusted net profit was 39.04 percent below budget, ROE decreased by 42.5 percent, and EPS dropped by 31 percent. This reflects a failure to achieve the outcome-based targets committed to the Board of Directors' meeting. Concurrently, strategic performance, KPI monitoring, risk management, and corporate communications lacked a systematic approach and showed no clear linkage to financial outcomes. The Board therefore considered that these issues affected the stability and confidence in the business, which are core components of the "orderly management and the best interests of the Company" as a public limited company.

Regarding the management of the Hemodialysis Center, the Chief Executive Officer (CEO) decided not to renew the contract with the incumbent service provider and planned for the Company to operate the center itself, anticipating higher returns. However, this initiative encountered regulatory licensing obstacles from the Ministry of Public Health and could not open for service within the scheduled timeframe. This impacted service continuity, created risks for ICU patients, affected customer confidence, and reduced the Company's revenue. Consequently, the Board viewed the lack of a comprehensive contingency plan for medical services involving patient safety as a significant risk management failure with a material impact on the overall business operations.



**Question 2:** "Will the abrupt change of the CEO prior to the expiration of the term cause any disruption or lack of agility in business management? Has the Board analyzed the potential negative impacts of this decision, and why does an immediate removal serve the 'best interests of the Company' better than waiting for the regular expiration of the term?"

**Answer 2:** Regarding the issue of changing the Chief Executive Officer (CEO) prior to the expiration of the term, the Board of Directors has carefully considered both the positive and negative impacts. The Board fully recognizes that changing a top executive may cause certain disruptions in continuity. However, when evaluated alongside the significant variance in financial performance, systemic issues in strategy and governance, and corporate governance concerns recorded in the minutes, the Board considers that taking prompt action helps mitigate administrative uncertainty. Furthermore, it signals the Board's strict commitment to maintaining the corporate governance standards of the Company. Therefore, the Board viewed that such action was taken for the best interests of the Company and its shareholders under those circumstances.

**Question 3:** "Prior to passing the removal resolution, did the Nomination and Remuneration Committee invite Dr. Jakkaphan to clarify or provide information? Furthermore, if a new candidate is nominated as a replacement, how will that individual's qualifications differ from the predecessor's in order to resolve the issues that the Board currently views as disorderly?"

**Answer 3:** Prior to passing the resolution, the Board of Directors carefully reviewed the evaluation results and supporting information based on official documents and facts recorded in the minutes. The consideration process was conducted in accordance with the Board's scope of authority under the employment contract and the Company's Articles of Association, and was by no means an arbitrary decision or a personal criticism.

Furthermore, the recruitment for the new position focuses on qualifications that directly address the identified systemic issues, namely: the ability to systematically link strategy with financial outcomes, proactive risk management in the medical services business, strict compliance with corporate governance principles, and alignment between the management and the Board of Directors. All of these qualifications aim to strengthen the long-term stability and confidence of the business.

**The meeting acknowledged the said suggestions.**

.....